» Articles » PMID: 16982882

Functional Dichotomy Between OX40 and 4-1BB in Modulating Effector CD8 T Cell Responses

Overview
Journal J Immunol
Date 2006 Sep 20
PMID 16982882
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Members of the TNFR family are thought to deliver costimulatory signals to T cells and modulate their function and survival. In this study, we compare the role of two closely related TNFR family molecules, OX40 and 4-1BB, in generating effector CD8 T cells to Ag delivered by adenovirus. OX40 and 4-1BB were both induced on responding naive CD8 T cells, but 4-1BB exhibited faster and more sustained kinetics than OX40. OX40-deficient CD8 T cells initially expanded normally; however, their accumulation and survival at late times in the primary response was significantly impaired. In contrast, 4-1BB-deficient CD8 T cells displayed hyperresponsiveness, expanding more than wild-type cells. The 4-1BB-deficient CD8 T cells also showed enhanced maturation attributes, whereas OX40-deficient CD8 T cells had multiple defects in the expression of effector cell surface markers, the synthesis of cytokines, and in cytotoxic activity. These results suggest that, in contrast to current ideas, OX40 and 4-1BB can have a clear functional dichotomy in modulating effector CD8 T cell responses. OX40 can positively regulate effector function and late accumulation/survival, whereas 4-1BB can initially operate in a negative manner to limit primary CD8 responses.

Citing Articles

An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL.

Prinz L, Riet T, Neureuther D, Lennartz S, Chrobok D, Hubbe H Cell Rep Med. 2024; 5(2):101421.

PMID: 38340727 PMC: 10897622. DOI: 10.1016/j.xcrm.2024.101421.


4-1BB immunotherapy: advances and hurdles.

Singh R, Kim Y, Lee S, Eom H, Choi B Exp Mol Med. 2024; 56(1):32-39.

PMID: 38172595 PMC: 10834507. DOI: 10.1038/s12276-023-01136-4.


Recently activated CD4 T cells in tuberculosis express OX40 as a target for host-directed immunotherapy.

Gress A, Ronayne C, Thiede J, Meyerholz D, Okurut S, Stumpf J Nat Commun. 2023; 14(1):8423.

PMID: 38110410 PMC: 10728168. DOI: 10.1038/s41467-023-44152-8.


A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy.

Chen C, Weng T, Huang H, Huang L, Huang K, Chen P J Exp Clin Cancer Res. 2023; 42(1):29.

PMID: 36691089 PMC: 9869520. DOI: 10.1186/s13046-023-02601-8.


4-1BB: A promising target for cancer immunotherapy.

Kim A, Nemeth M, Lim S Front Oncol. 2022; 12:968360.

PMID: 36185242 PMC: 9515902. DOI: 10.3389/fonc.2022.968360.